Arch PharmalabsPharmaceuticals
Returns1M
+23.43%
IPO Status
Pre-IPO only
Healthcare & Pharmaceuticals Unlisted Shares In India
Defensive sector supported by rising healthcare demand, aging populations, research spending, and regulatory approvals
Defensive sector supported by rising healthcare demand, aging populations, research spending, and regulatory approvals
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved
Showing 7 out of 14 Companies
Updated 4 hours ago
| Company | Subsector | Market cap (₹ Cr) | % Change | Revenue YoY (%) | PAT (₹) | IPO Status |
|---|---|---|---|---|---|---|
Arch Pharmalabs | Pharmaceuticals | 1,611.75 | 23.4% | 135.2% | 122.11 | Pre-IPO only |
Gynofem Healthcare and Pharmaceutical | Women's Health | 605.20 | 15.1% | 133.3% | -2.09 | Pre-IPO only |
Veeda Clinical Research | Diagnostics & CRO | 2,986.30 | 2.3% | 52.2% | -66.80 | Pre-IPO only |
Down Town Hospital | Hospitals & Healthcare Delivery | 1,104.45 | 0.3% | 9.5% | 5.83 | Pre-IPO only |
Anglo French Drugs and Industries | Pharmaceuticals | 255.83 | — | 225.8% | 22.85 | Pre-IPO only |
API Holdings (Pharmeasy) | Healthtech & Digital Health | 3,616.75 | — | 3.8% | -1,593.19 | Pre-IPO only |
Martin and Harris Laboratories | Pharma & Drug Manufacturing | 337.27 | — | 21.3% | 40.43 | Pre-IPO only |
India’s healthcare and pharmaceutical sector is driven by rising healthcare spending, increasing chronic disease prevalence, and growing demand for quality medical services. The sector includes pharmaceuticals, hospitals, diagnostics, medical devices, contract research, and healthcare technology companies. India is one of the world's largest suppliers of generic medicines and continues to benefit from strong export demand, growing domestic healthcare consumption, and expanding healthcare infrastructure.
| Company name | Pre-IPO Price | Listing Price | Pre-IPO Return |
|---|---|---|---|
 Concord BiotechListed 2023 | ₹700 – ₹800 | ₹900.05 | ~1.21x |
 Blue Jet HealthcareListed 2023 | ₹300 – ₹350 |
Explore unlisted and pre-IPO companies across pharmaceuticals, hospitals, diagnostics, medical devices, and healthcare services before public listing.
You can review company overview, product portfolio, regulatory approvals, growth drivers, valuation insights, and financial performance.
Compare revenue growth, product pipeline, market opportunity, profitability, management quality, and regulatory track record.
Rising healthcare spending, aging population, chronic disease treatment demand, pharma exports, and healthcare infrastructure expansion.
Key risks include regulatory delays, pricing pressure, product concentration, and R&D execution challenges.
Register on Precize, complete your KYC, explore available opportunities, and place your order to invest in unlisted healthcare shares online.
| ₹395.85 |
| ~1.14x |
 Sai Life SciencesListed 2024 | ₹500 – ₹550 | ₹650 | ~1.18x |
Delays in approvals can impact product launches and revenue growth.
Drug price controls may affect profitability for pharma companies.
Product development failures can impact future earnings potential.
